WallStreetZenWallStreetZen

NASDAQ: CSTL
Castle Biosciences Inc Stock Forecast, Predictions & Price Target

Analyst price target for CSTL

Based on 6 analysts offering 12 month price targets for Castle Biosciences Inc.
Min Forecast
$40.00+41.34%
Avg Forecast
$52.17+84.34%
Max Forecast
$80.00+182.69%

Should I buy or sell CSTL stock?

Based on 6 analysts offering ratings for Castle Biosciences Inc.
Strong Buy
Strong Buy
2 analysts 33.33%
Buy
4 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CSTL stock forecasts and price targets.

CSTL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
ScotiaBank
Top 21%
80
BuyInitiates Coverage On$54.00+90.81%2023-01-05
Baird
Top 3%
98
BuyMaintains$41.00+44.88%2022-11-03
Baird
Top 27%
74
BuyMaintains$48.00+69.61%2022-08-09
SVB Leerink
Bottom 2%
2
BuyMaintains$50.00+76.68%2022-08-09
KeyBanc
Top 9%
92
Strong BuyMaintains$40.00+41.34%2022-05-11
Canaccord Genuity
Bottom 1%
1
Strong BuyMaintains$80.00+182.69%2022-04-05

1 of 1

Forecast return on equity

Is CSTL forecast to generate an efficient return?
Company
-13.9%
Industry
-21.44%
Market
47.84%
CSTL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CSTL forecast to generate an efficient return on assets?
Company
-12.49%
Industry
12%
CSTL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CSTL earnings per share forecast

What is CSTL's earnings per share in the next 2 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$3.08
Avg 2 year Forecast
-$2.17

CSTL revenue forecast

What is CSTL's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$158.3M+27.95%
Avg 2 year Forecast
$195.9M+58.3%
CSTL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CSTL revenue growth forecast

How is CSTL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
27.95%
Industry
5.62%
Market
70.63%
CSTL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CSTL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CSTL vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
CSTL$28.30$52.17+84.34%Strong Buy
NVTA$2.62$4.63+76.53%Sell
CDNA$16.54$35.50+114.63%Strong Buy
MXCT$5.77$11.00+90.64%Strong Buy
SENS$1.20$3.00+150.00%Buy

Castle Biosciences Stock Forecast FAQ

Is Castle Biosciences Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: CSTL) stock is to Strong Buy CSTL stock.

Out of 6 analysts, 2 (33.33%) are recommending CSTL as a Strong Buy, 4 (66.67%) are recommending CSTL as a Buy, 0 (0%) are recommending CSTL as a Hold, 0 (0%) are recommending CSTL as a Sell, and 0 (0%) are recommending CSTL as a Strong Sell.

If you're new to stock investing, here's how to buy Castle Biosciences stock.

What is CSTL's earnings growth forecast for 2023-2024?

(NASDAQ: CSTL) Castle Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 33.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 84.98%.

Castle Biosciences's earnings in 2023 is -$52,950,000.On average, 3 Wall Street analysts forecast CSTL's earnings for 2023 to be -$81,162,854, with the lowest CSTL earnings forecast at -$88,277,780, and the highest CSTL earnings forecast at -$67,987,066.

In 2024, CSTL is forecast to generate -$57,182,920 in earnings, with the lowest earnings forecast at -$68,514,098 and the highest earnings forecast at -$45,851,742.

What is CSTL's revenue growth forecast for 2023-2024?

(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of 27.95% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 70.63%.

Castle Biosciences's revenue in 2023 is $123,740,000.On average, 2 Wall Street analysts forecast CSTL's revenue for 2023 to be $4,171,981,512, with the lowest CSTL revenue forecast at $4,163,549,008, and the highest CSTL revenue forecast at $4,180,414,017.

In 2024, CSTL is forecast to generate $5,161,878,465 in revenue, with the lowest revenue forecast at $5,132,496,458 and the highest revenue forecast at $5,191,260,472.

What is CSTL's forecast return on assets (ROA) for 2023-2024?

(NASDAQ: CSTL) forecast ROA is -12.49%, which is lower than the forecast US Diagnostics & Research industry average of 12%.

What is CSTL's Price Target?

According to 6 Wall Street analysts that have issued a 1 year CSTL price target, the average CSTL price target is $52.17, with the highest CSTL stock price forecast at $80.00 and the lowest CSTL stock price forecast at $40.00.

On average, Wall Street analysts predict that Castle Biosciences's share price could reach $52.17 by Jan 5, 2024. The average Castle Biosciences stock price prediction forecasts a potential upside of 84.34% from the current CSTL share price of $28.30.

What is CSTL's Earnings Per Share (EPS) forecast for 2023-2024?

(NASDAQ: CSTL) Castle Biosciences's current Earnings Per Share (EPS) is -$2.05. On average, analysts forecast that CSTL's EPS will be -$3.08 for 2023, with the lowest EPS forecast at -$3.35, and the highest EPS forecast at -$2.58. In 2024, CSTL's EPS is forecast to hit -$2.17 (min: -$2.60, max: -$1.74).

What is CSTL's forecast return on equity (ROE) for 2023-2024?

(NASDAQ: CSTL) forecast ROE is -13.9%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.